Joe Rogan TRT: What Clinicians Should Tell Patients Who Ask

Why Joe Rogan's Name Comes Up in the Exam Room

Patients are listening. The Joe Rogan Experience is one of the most downloaded English-language podcasts on earth, and Rogan has discussed testosterone replacement therapy, NAD+ drips, peptides like BPC-157, and human growth hormone across dozens of episodes. When a 48-year-old male patient walks in asking about "low T," there is a real chance he heard about it from Rogan first, not from a health reporter or his previous doctor.

That is not inherently bad. Celebrity health discourse can lower the barrier to seeking care. The clinical risk arises when patients arrive with fixed expectations about specific regimens, doses, or outcomes that may not apply to their individual physiology.

What Rogan Has Actually Said (and What Is Inference)

Rogan has explicitly named testosterone on multiple podcast episodes, including episodes with guests such as rheumatologist and longevity physician Mark Gordon and anti-aging specialist Peter Attia. He has described using "testosterone, HGH, and a bunch of other things" and has mentioned NAD+ IV infusions as a recovery tool. These are documented public statements.

What is inference: his specific protocol, doses, and lab values are not public. No verified prescription record exists. Clinicians should not assume patients need what Rogan describes taking, because Rogan's physiology, comorbidities, and clinical picture are not theirs.

The Parasocial Prescription Problem

When patients internalize a celebrity's self-reported regimen, they can arrive with what might be called a "parasocial prescription," a specific drug and dose they feel entitled to because someone they trust takes it. A 2021 analysis in the Journal of Medical Internet Research found that celebrity health disclosures increased Google searches for the disclosed condition by a mean of 47% within 72 hours, though it did not measure downstream prescribing appropriateness. Naming this dynamic explicitly with patients, without dismissing their interest, keeps the conversation clinical rather than adversarial.

Testosterone Replacement Therapy: The Evidence Base Patients Deserve

TRT is not fringe medicine. The Endocrine Society's 2018 Clinical Practice Guideline on testosterone therapy in men with hypogonadism recommends treatment for men with consistently low serum testosterone and unambiguous symptoms, with the goal of restoring levels to the mid-normal range for healthy young men (400 to 700 ng/dL) [1].

Who Actually Qualifies

Biochemical hypogonadism is defined as a total morning testosterone below 300 ng/dL on two separate measurements taken at least one week apart, accompanied by symptoms: reduced libido, fatigue, depressed mood, loss of lean mass, or impaired concentration [1].

The 2018 Endocrine Society guideline states directly: "We suggest against making a diagnosis of androgen deficiency in men with morning total testosterone levels consistently above 400 ng/dL." Patients who arrive quoting Joe Rogan but whose testosterone sits at 520 ng/dL are not candidates by any major guideline. That is the honest answer, and patients generally accept it when the guideline is named.

Standard Dosing and Formulations

Testosterone cypionate and testosterone enanthate remain the most prescribed injectable forms in the United States. The Endocrine Society guideline recommends starting doses of 75 to 100 mg IM weekly or 150 to 200 mg IM every two weeks [1]. Topical gels (testosterone 1.62%, such as AndroGel) deliver 20.25 to 81 mg daily. Subcutaneous pellets (Testopel, 75 mg per pellet) are placed every 3 to 6 months.

Oral testosterone undecanoate (Jatenzo, FDA-approved 2019) offers a non-injectable option but requires dose titration based on serum levels and carries a labeling warning for blood pressure increases [2].

The TRAVERSE Trial: The Most Important Recent Data

The cardiovascular safety question dominated TRT medicine for more than a decade after a 2010 Basaria et al. Trial in the New England Journal of Medicine was stopped early due to a cardiovascular signal in older men with limited mobility [3]. That study (N=209) was small and enrolled a high-risk cohort.

The TRAVERSE trial (N=5,204), published in the New England Journal of Medicine in 2023, is the definitive answer so far [4]. Men aged 45 to 80 with hypogonadism and elevated cardiovascular risk were randomized to transdermal testosterone 1.62% gel or placebo for a mean of 22 months. The primary composite endpoint of cardiovascular death, myocardial infarction, stroke, or coronary revascularization was 7.0% in the testosterone group vs. 7.3% in placebo (hazard ratio 0.96; 95% CI 0.78 to 1.17), meeting non-inferiority. Testosterone did not increase major adverse cardiovascular events in this population.

TRAVERSE also found higher rates of atrial fibrillation (3.5% vs. 2.4%), pulmonary embolism (0.9% vs. 0.5%), and acute kidney injury (2.3% vs. 1.5%) in the testosterone arm. These signals require patient-level risk stratification before initiating therapy.

Monitoring TRT: The Protocol Patients Will Not Hear on a Podcast

Initiating TRT without a monitoring plan is where outcomes diverge. The Endocrine Society recommends specific surveillance checkpoints [1].

Baseline Labs Before Any Prescription

• Total testosterone (morning draw, two separate measurements)
• Free testosterone (calculated or equilibrium dialysis)
• LH and FSH (to distinguish primary from secondary hypogonadism)
• Hematocrit and hemoglobin
• PSA (for men over 40)
• Comprehensive metabolic panel
• Lipid panel
• Estradiol (particularly if obesity is present)

On-Treatment Monitoring Schedule

At 3 to 6 months after starting: recheck total testosterone (mid-cycle for injectables), hematocrit, and PSA. Target serum testosterone 400 to 700 ng/dL. If hematocrit exceeds 54%, pause therapy and investigate secondary causes before resuming at a lower dose [1].

At 12 months: repeat the full panel, including DRE and PSA for men over 40. Annual monitoring continues thereafter.

Managing Elevated Hematocrit and Estradiol

Polycythemia is the most common dose-limiting adverse effect of TRT. Hematocrit rises in roughly 10 to 20% of patients on injectable testosterone, driven by erythropoietic stimulation. The FDA's prescribing information for testosterone products includes a boxed warning about this risk and its association with venous thromboembolism [2].

Estradiol conversion through peripheral aromatization rises with testosterone dose and with adipose tissue. Aromatase inhibitors such as anastrozole 0.5 to 1 mg twice weekly are sometimes used off-label to manage symptomatic estradiol elevation, though routine use is not supported by guideline recommendations and may adversely affect bone mineral density if estradiol is suppressed too aggressively.

NAD+: What the Evidence Says and What It Does Not

Rogan has discussed NAD+ IV infusions for energy and recovery. Nicotinamide adenine dinucleotide is a coenzyme central to oxidative phosphorylation and a substrate for sirtuins and PARP enzymes implicated in DNA repair.

The Current Evidence Gap

The human trial data for IV NAD+ as a therapeutic modality is thin. A 2023 pilot study (N=30) published in Aging found that IV nicotinamide riboside (a NAD+ precursor) raised whole-blood NAD+ levels by 40 to 50% at 7 days, but no clinical outcomes were measured [5]. The National Institute on Aging is funding larger trials, but as of mid-2025, no phase III RCT has demonstrated clinical benefit of IV NAD+ supplementation in healthy aging men.

What to Tell Patients

IV NAD+ is not FDA-approved for any indication. The cost (typically $250, $700 per infusion) is not covered by insurance. Patients should understand they may experience a temporary flush, nausea, or chest tightness during infusion, and that the durability of any NAD+ level increase beyond the infusion period is unclear from current data. This is an area where honest uncertainty is the correct clinical posture.

Peptides: BPC-157, Ipamorelin, and the Regulatory Reality

Rogan has mentioned peptides including BPC-157 (body protection compound) on his podcast. Patients increasingly arrive having already ordered these compounds online.

BPC-157: Mostly Rodent Data

BPC-157 is a 15-amino-acid synthetic peptide derived from a protein found in gastric juice. Animal studies have shown accelerated tendon healing and gastroprotective effects in rodent models [6]. No peer-reviewed phase II or III human clinical trial supports its use for musculoskeletal injury or gut health in humans as of 2025.

Ipamorelin and Sermorelin

Growth hormone secretagogues such as ipamorelin (a ghrelin receptor agonist) and sermorelin (a GHRH analogue) stimulate pituitary GH release. The FDA has not approved these peptides for anti-aging or body composition indications. Sermorelin (Geref) was previously FDA-approved for growth hormone deficiency in children but was withdrawn from the US market by the manufacturer in 2008. Compounded versions circulate widely.

The FDA Compound Pharmacy Enforcement Issue

In 2023, the FDA placed several peptides, including BPC-157, on its list of drugs that may not be compounded under section 503A or 503B of the Federal Food, Drug, and Cosmetic Act because they are not components of any FDA-approved drug and do not appear on the 503B bulk drug substances list [2]. Prescribing or recommending compounded BPC-157 currently carries regulatory risk for the clinician.

The framework below summarizes how to triage a patient who arrives citing Joe Rogan's regimen, based on which compound they are asking about.

| Patient Request | Evidence Level | FDA Status | Guideline-Supported Response | |---|---|---|---| | TRT (symptomatic, low testosterone confirmed) | High (multiple RCTs, Endocrine Society Guideline 2018) | Approved multiple formulations | Initiate after two-morning draws confirm <300 ng/dL plus symptoms | | TRT (normal testosterone, "optimization") | Low (no RCT in eugonadal men) | Approved but off-label use | Decline; explain guideline threshold | | NAD+ IV infusions | Very low (pilot data only) | Not FDA-approved for indication | Acknowledge interest; explain evidence gap | | BPC-157 | Preclinical only | Cannot be compounded; no approval | Advise against; cite FDA enforcement notice | | Ipamorelin / sermorelin | Low (small studies, no phase III) | Not FDA-approved for adults | Off-label; informed consent required |

Having the Conversation: A Clinical Communication Guide

Patients who mention Joe Rogan are not asking you to become Joe Rogan's physician. They are asking whether what they heard applies to them. The conversation goes better when you separate the compound from the celebrity.

Step 1: Validate the Curiosity Without Validating the Claim

"That's a question I get a lot. Let's look at your numbers and symptoms first, because the right answer depends entirely on your physiology."

This opens the door without conceding that Rogan's reported regimen is the goal.

Step 2: Anchor to Objective Data

Run the labs. A total testosterone of 280 ng/dL on two morning draws, combined with fatigue, reduced libido, and loss of lean mass, is a clinical diagnosis. That diagnosis stands on its own, independent of any podcast. Conversely, a patient at 540 ng/dL with vague fatigue is not a TRT candidate by guideline criteria, and naming the guideline is more persuasive than a clinician's opinion alone.

Step 3: Address the "Optimization" Frame Directly

Rogan's discourse, and much of the longevity-medicine space, frames hormones as performance optimization tools rather than deficiency treatments. The Endocrine Society's 2018 guideline explicitly advises against prescribing testosterone to men who do not have a clinical and biochemical diagnosis of hypogonadism, stating that the benefits in eugonadal men are not established and the long-term risks are unknown [1].

Patients can be told: "The evidence is clear for men whose testosterone is genuinely low. For men in the normal range, we do not have long-term safety data, and the benefit studies have not been done."

Step 4: Discuss Fertility Impact

Exogenous testosterone suppresses LH and FSH, reducing intratesticular testosterone and impairing spermatogenesis. The American Urological Association's 2022 guideline on male infertility identifies TRT as a cause of secondary hypogonadism and recommends against its use in men desiring fertility [7]. Patients under 45 in particular should hear this clearly before initiating treatment.

Specific Numbers Patients Should Know Before Starting TRT

Concrete data reduces the gap between podcast enthusiasm and clinical realism.

• 14% to 16% of men who start testosterone therapy develop a hematocrit above 50%, typically within the first 6 months of injectable therapy [1].
• In TRAVERSE (N=5,204), pulmonary embolism occurred in 0.9% of testosterone-treated men vs. 0.5% placebo over 22 months, a statistically significant difference (P<0.05) [4].
• Sperm concentration drops to zero in approximately 65% of men using exogenous testosterone within 6 months, per a 2021 systematic review in Andrology (N=1,549 across 30 studies) [8].
• Lean mass gain from TRT in hypogonadal men averaged 1.6 kg above placebo at 12 months in a Cochrane meta-analysis of 11 trials, while fat mass decreased by 1.1 kg [9].
• Mood and quality of life scores improved significantly (P<0.001) in hypogonadal men receiving TRT vs. Placebo in the Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled trials (N=790 men aged 65+) [10].

These numbers give patients something to compare against podcast anecdote. They also make the risk-benefit discussion concrete.

HGH: Rogan Has Mentioned It. Here Is the Clinical Reality.

Human growth hormone (somatropin) is FDA-approved for adult growth hormone deficiency, a diagnosis requiring both biochemical confirmation (stimulation testing with peak GH <5 mcg/L) and clinical features. It is not approved for anti-aging, athletic performance, or body composition in adults without confirmed GHD [2].

IGF-1 levels fall with age, and this decline is real. But a 2007 systematic review in the Annals of Internal Medicine (N=220 across 31 trials) found that GH supplementation in healthy older adults produced modest increases in lean mass and decreases in fat mass, but also increased rates of edema (49%), arthralgias (42%), carpal tunnel syndrome (18%), and gynecomastia (10%) without improving strength, functional capacity, or quality of life [11]. The authors concluded: "The evidence does not support use of GH for antiaging."

Prescribing HGH for anti-aging purposes without a confirmed GHD diagnosis violates FDA labeling and carries DEA Schedule II-adjacent scrutiny, as somatropin is a controlled substance under the Anabolic Steroids Control Act of 1990 as interpreted by the DEA.